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Green tea or green tea extract (GT/GTE) has been demonstrated to reduce insulin resistance and improve glycemic control. How-
ever, evidence for this health beneficial effect is inconsistent. This systematic review evaluated the effect of GT/GTE on insulin re-
sistance and glycemic control in people with pre-diabetes/type 2 diabetes mellitus (T2DM). Ovid MEDLINE, Embase, AMED, 
Web of Science, and the Cochrane Library were searched up to April 2017 for randomised controlled trials of participants with 
pre-diabetes or T2DM, where the intervention was GT/GTE. Meta-analysis was performed to assess the standardised mean dif-
ference (SMD) in biomarkers of insulin resistance and glycemic control between GT/GTE and placebo groups. Six studies 
(n=382) were pooled into random-effects meta-analysis. Overall, no differences were found between GT/GTE and the placebo 
for glycosylated hemoglobin (HbA1c: SMD, –0.32; 95% confidence interval [CI], –0.86 to 0.23), homeostatic model assessment 
for insulin resistance (HOMA-IR: SMD, 0.10; 95% CI, –0.17 to 0.38), fasting insulin (SMD, –0.25; 95% CI, –0.64 to 0.15), and 
fasting glucose (SMD, –0.10; 95% CI, –0.50 to 0.30). No evidence support the consumption of GT/GTE could reduce the levels of 
HbA1c, HOMA-IR, fasting insulin, or fasting glucose in people with pre-diabetes/T2DM. However, the studies included were 
small and of varying quality. 
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INTRODUCTION
Accounting for 90% of cases of diabetes, type 2 diabetes melli-
tus (T2DM) is a chronic metabolic disorder that is character-
ized by insulin resistance and high blood glucose levels (hyper-
glycemia) [1,2]. The number of cases of T2DM has almost 
quadrupled since 1980 and it has been become a major global 
health challenge [3]. The chronic hyperglycemia of T2DM is 
associated with long-term complications, including the dam-
age, dysfunction, and failure of heart, kidneys, blood vessels, 
and other organs [4]. Pre-diabetes can precede T2DM by 10 to 
20 years [2,5,6], and research suggests that T2DM could be 
largely preventable through dietary and lifestyle changes [7,8]. 
Tea is the second most commonly consumed beverage in the 
world aside from water [9]. In comparison to black tea and 
oolong tea, green tea (GT) contains greater quantities of cate-
chins, which are strong antioxidants in vitro and in vivo. The 
most abundant catechin found in GT is epigallocatechin gal-
late (EGCG), which is thought to have many health benefits 
including a role in body weight control and diabetes preven-
tion [10]. Experimental animal studies have shown that green 
tea extract (GTE) can increase insulin sensitivity and lower 
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blood glucose levels in diabetic (db/db) mice [11,12], whilst in 
humans, epidemiological studies suggest that long-term con-
sumption of GT may be associated with a reduction of the in-
cidence of diabetes [13,14]. A number of randomized con-
trolled trials (RCTs) have reported that daily consumption of 
GTE may enhance oral glucose tolerance in healthy people as 
well as reduce fasting plasma glucose and glycosylated hemo-
globin (HbA1c) levels in people at risk of diabetes [15-19]. 
Therefore, GT or GTE may have a role to play in reducing in-
sulin resistance and improving glycemic control in people with 
T2DM. 
However, systematic reviews and meta-analyses investigat-
ing the relationship between GT consumption and insulin re-
sistance and glycemic control have reported mixed findings. 
Whilst one meta-analysis has concluded that GT consumption 
is effective in decreasing fasting glucose and glycemic control 
(HbA1c concentration) in both healthy subjects and patients 
with obesity or metabolic syndrome [20]. Wang et al. [21] 
found no effect of GT consumption on fasting glucose, insulin, 
glycemic control or insulin resistance in participants both 
with, and at risk of, T2DM. In order to clarify the potential of 
GT in improving metabolic health in people with T2DM, fur-
ther evaluation of the evidence for this health beneficial effect 
of GT on people with a clinical diagnosis of T2DM or pre-dia-
betes are needed. The objectives of this study are thus: (1) to 
collate and evaluate the evidence for the effect of GT or GTE 
on insulin resistance and glycemic control in people with pre-
diabetes or T2DM; (2) conduct a meta-analysis to assess the 
standardised mean difference (SMD) in biomarkers of insulin 
resistance and glycemic control between GT/GTE and placebo 
group.
METHODS 
Search strategy
The following electronic databases were searched from their 
inception upto April 2017: Ovid MEDLINE (1946 to present), 
Ovid Embase (1974 to April 2017), AMED (1985 to April 
2017), the Web of Science (Core Collection), The Cochrane Li-
brary (2017). Search terms were: ‘green tea,’ ‘GTE,’ ‘EGCG,’ 
‘epigallocatechin,’ ‘epigallocatechin,’ ‘epicatechin,’ ‘random,’ 
‘RCT,’ ‘insulin resistance,’ ‘glycemic control,’ ‘diabetes,’ and 
‘T2DM’ (Appendix 1 for electronic search strategy). The refer-
ence list from all selected articles were hand-searched for fur-
ther relevant studies. The first 20 pages of Google Scholar were 
hand-searched for additional studies. 
Selection criteria
Criteria for considering studies for this review were: (1) ran-
domised controlled trials; (2) participants were people with 
pre-diabetes (fasting blood glucose 110 to 125 mg/dL [6.1 to 
6.9 mM/L]) or T2DM; (3) the interventions were GT bags, 
GTEs or aqueous beverages where the chemical composition 
was provided; and (4) comparable measures for insulin resis-
tance and glycemic control were provided. In addition, studies 
that used a cross-over design were only included if the results 
of the period before the cross-over were presented separately, 
in which data from the first phase were analysed.
Excluded studies
Studies were excluded if they were: (1) animal trials; (2) obser-
vational studies; (3) review articles; (4) the experimental bever-
age contains other kinds of tea in addition to GT; (5) the prepa-
ration of GT contained ingredients in addition to GT or its nat-
ural constituents of catechins and caffeine; (6) the intervention 
or treatment included a combination of GT and physical activ-
ity; and (7) the participants’ clinical state was not specified.
Data extraction and management
Data were extracted independently by two reviewers (J.Y. and 
A.R.C.) and confirmed by a third reviewer (P.S.) using a form 
adapted from Cochrane Data Extraction Form for Interven-
tion Review. Specific information, including the study design, 
the characteristics of participants, and study outcomes, were 
extracted and recorded. A summary of the characteristic s of 
the studies and the results are presented in Table 1. Any dis-
crepancies were resolved through discussion between the re-
viewers.
All extracted data were entered into the RevMan 5.3 (Co-
chrane, London, UK) for further analysis.
Methodological quality and risk of bias assessment
Assessment of the reporting quality of the included studies was 
based on the CONSORT (CONsolidated Standards of Report-
ing Trials) 2010 checklist [22]. Studies were categorized as (1) 
high quality, with more than 75% compliance to the checklist; 
(2) moderate quality, with 50% to 75% compliance to the 
checklist; (3) low quality, with less than 50% compliance to the 
checklist; and (4) very low quality, with no more than 30% 
compliance to the checklist. 
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The risk of bias of each included study was assessed under 
the criteria in the ‘risk of bias assessment tool’ [23]. For each 
entry, the risk of bias was assessed as ‘low risk,’ ‘high risk,’ or 
‘unclear risk.’ The assessment process was conducted by J.Y. 
and A.R.C. independently. A meeting was organized to discuss 
any disagreements.
Data analysis
The SMD was calculated based on the standard equation to 
combine trials which measured the same outcome using dif-
ferent methods [23]. The pooled estimates of SMD were calcu-
lated using a random-effects model with 95% confidence in-
terval (CI) and inverse variance weights. The statistical hetero-
geneity was examined and measured using the I² statistic, and 
subgroup analysis was considered when two or more trials 
contributed data. The pre-specified subgroup analysis was for 
decaffeinated GTE versus GT beverage/extract. Dealing with 
the missing data was based on the technique given by Co-
Table 1. Characteristics of the included studies
Study Design Participant Age, yr Intervention Control Treatment duration
Quality of 
reportinga
Fukino et al. 
(2008) [16]
   Japan
Crossover T2DM and 
pre-diabetes 
patients 
(n=60)
32–73 GTE beverage (456 mg 
catechins; 102 caffeine)
Water 8 weeks Moderate to 
high
Mirzaei et al. 
(2009) [27] 
   Iran
Parallel T2DM patients 
(n=72)
54.56±11.23 GTE capsule (240 mg 
polyphenols; 150 mg 
caffeine)
Placebo (cellulose cap-
sules)
8 weeks Low
Nagao et al.
    (2009) [30] 
   Japan
Parallel T2DM patients 
(n=50)
64.9±1.6
62.8±2.2
GTE beverage (528.8 mg 
catechins; 75 mg caf-
feine)
GTE beverage (96.3 mg 
catechins; 72.3 mg 
caffeine)
12 weeks Moderate to 
high
Huyen et al. 
(2010) [24] 
   Vietnam
Parallel T2DM patients 
(n=24)
63.5±6.5
57.2±8.2
Gynostemma pentaphyl-
lum tea 6 g/day (3 g/
packet, twice a day)
GT 6 g/day (3 g/packet, 
twice a day)
12 weeks High
Hsu et al. 
   (2011) [17] 
   China
Parallel T2DM patients 
(n=68)
20-65 DGTE capsule (856 mg 
EGCG)
Placebo (cellulose cap-
sules)
16 weeks High
Huyen et al. 
(2013) [25] 
   Vietnam
Crossover T2DM patients 
(n=16)
58.8±5.9
58.1±6.6
Gynostemma pentaphyl-
lum tea 6 g/day (3 g/
packet, twice a day)
GT 6 g/day (3 g/packet, 
twice a day)
8 weeks Moderate to 
high
Mousavi et al. 
(2013) [28]
   Iran
Parallel T2DM patients 
(n=63)
35–65 GT (4 cups/day); GT (2 
cups/day)
Water (no tea drinks) 8 weeks Moderate to 
high
Lasaite et al. 
(2014) [26]
   Lithuanian
Parallel T2DM patients 
(n=56)
37–78 GTE capsules (200 mg 
polyphenols)
Placebo (cellulose cap-
sules)
18 months Low
Liu et al. (2014) 
[19] China
Parallel T2DM patients 
(n=77)
55.0±6.6
53.5±7.0
DGTE capsule (856.8 mg 
EGCG)
Placebo (cellulose cap-
sules)
16 weeks High
Mozaffari-
   Khosravi et al.
    (2014) [29]
   Iran
Parallel T2DM patients 
(n=94)
52.2±6.7
52.1±6.0
GT bag (3 g/day) Sour tea bag (3 g/day) 4 weeks High
Ryu et al. 
   (2006) [31]
   Korea
Crossover T2DM patients 
(n=55)
53.9±7.7 GTE beverage (9 g GT) Water 4 weeks Very low
Values are presented as range or mean±standard deviation.
T2DM, type 2 diabetes mellitus; GTE, green tea extract; GT, green tea; DGTE, decaffeinated green tea extract; EGCG, epigallocatechin gallate.
aAssessed by the CONSORT (CONsolidated Standards of Reporting Trials) checklist for randomized controlled trials.
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chrane handbook with the following principles [23]: (1) ob-
taining the missing data from the other available data provided 
in the trial; (2) substituting the missing data with replacement 
values; and (3) analysing only the available data. 
Ethical approval
The study was approved by the Human Research Ethics Com-
mittee of the Centre for Exercise, Nutrition and Health Scienc-
es, University of Bristol (Ethics Approval Number: 013-15).
RESULTS
Results of the search
A description of the selection process is outlined in Fig. 1 in 
the form of the PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) flowchart (Appendix 1, 
search strategy MEDLINE). In total, 829 references were iden-
tified from the research of which eleven of the 23 full-text stud-
ies that were examined were included in this review [16,17,19, 
24-31]. The characteristics of the included studies are provided 
in Tables 1 and 2. The 12 excluded studies [32-43] with the rea-
son for exclusion were recorded in Table 3.
Trial characteristics
Trial characteristics for all the included studies are illustrated 
in Table 1. Participants of 10 studies were T2DM patients 
(n=635) between the age of 20 to 78 years [17,19,24-31] while 
one study enrolled the patients with T2DM and pre-diabetes 
[16]. Additionally, 10 of the studies were conducted in Asian 
countries, including China [17,19], Japan [16,30], Iran [27-29], 
Korea [31], and Vietnam [24,25], and one study was conducted 
in Lithuania [26]. The type of the GT or GTE used in the 11 
studies included GTE beverage [16,30,31], four of the studies 
used GT bags [24,25,28,29], two studies used GTE capsules 
[26,27], and two studies used decaffeinated GTE capsules [17, 
19]. As the most common test for glucose control, the HbA1c 
(%) was measured in seven studies [16,17,19,24,26,27,30] 
while the fasting blood glucose (FG) was been measured in 10 
studies [16,17,19,24,25,27-29,30,31]. Eight studies provided 
data for the change of fasting insulin (FI) [16,17,19,24,25,27, 
30,31] and six studies measured the homeostatic model assess-
ment for insulin resistance (HOMA-IR) [16,17,19,24,29,31].
Quality of reporting
Overall, four studies were judged as being of high reporting 
quality [17,19,24,29], four studies were of moderate to high 
quality [16,25,28,30], and two were of low quality [26,27]. One 
of the study was of very low quality [31], in which only 30% of 
items met the assessment criteria. Thus, this study was exclud-
ed from further data analysis. 
For the risk of bias assessment (Fig. 2), the majority of stud-
ies were rated as low risk of bias on most assessed items. Most 
of the information from the studies was categorized as having 
an unclear bias for key elements of randomization. Two studies 
[16,29] were classified as high risk of performance bias without 
blinding. Two studies were judged to be at high risk of bias for 
the allocation concealment, in which the participants were 
matched by gender through the allocation process [24,29]. 
High attrition bias was found in two studies [26,27].
829 Total records identi-
fied through electronic 
databases searching
668 Potentially relevant 
studies were screened
23 Full text articles as-
sessed for eligibility
6 Studies included in me-
ta-analysis
11 Eligible studies
161 Duplicates removed
645 Excluded by title and 
abstract
Reasons for exclusion:
143 Clearly irrelevant 
based on inclusion
154 Not randomised 
controlled trials
183 Not use the green tea
165 Not in patients with 
type 2 diabetes
12 Excluded after the 
screening of the full-text
Reasons for exclusion:
1 No targeted outcome
1 Interventions were 
combined green tea 
and black tea
1 Interventions were 
combines green tea 
and other anti-oxi-
dants
6 Participants are neither 
type 2 diabetes nor 
pre-diabetes
3  Not randomised con-
trolled trials
Fig. 1. Flow-chart of study selection and exclusion in details. 
Adapted from www.mdpi.com/link.
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Meta-analysis
In total, data from six studies [16,17,19,26-28] that compared 
GT supplements with placebos were included in these meta-
analyses. Four studies were excluded from the meta-analyses 
since the beverages in these studies included sour tea [29], Gy-
nostemma pentaphyllum tea [24,25], and lower dose of GT 
Table 2. Outcomes and results of the included studies
Study Outcomes Assessment point Results (intervention vs. control)
Fukino et al. 
   (2008) [16]
FI, FG, HOMA-IR, 
HbA1c
T0: baseline 
T1: 4 weeks
HbA1c (%): T0: 6.2±2.0 vs. 6.1±1.3, P=0.03; T1: 5.9±1.9 vs. 6.1±1.4 
FG (mmol/L): T0: 7.5±3.5 vs. 7.7±2.5, P=0.18; T1: 7.0±2.7 vs. 7.2±1.6 
FI (µU/mL): T0: 8.8±7.3 vs. 10.3±10.1, P=0.41; T1: 7.4±7.3 vs. 6.5±4.0 
HOMA-IR: T0: 3.0±2.9 vs. 3.7±4.4, P=0.35; T1: 2.4±2.5 vs. 2.1±1.3
Mirzaei et al. 
   (2009) [27]
HbA1c, FI, FG T0: baseline
T1: 8 weeks
HbA1c (%): T0: 7.21±1.63 vs. 7.61±2.04, P=0.3; T1: 7.25±1.87 vs. 8.17±2.09, 
P=0.05
FG (mmol/L): T0: 162.71±65.72 vs. 175.90±62.39, P=0.7; T1: 169.07±70.60 
vs. 185.51±72.75, P=0.15
FI (µU/mL): T0: 15.92±7.42 vs. 14.13±4.39, P=0.3; T1: 16.70±8.99 vs. 
15.57±7.03, P=0.06
Nagao et al. 
   (2009) [30]
FI, FG, HbA1c T0: baseline
T1: 12 weeks
T0–T1 Changes:
HbA1c (%): –0.37±0.12 vs. –0.01±0.17
FG (mg/dL): –8.0±4.7 vs. 4.9±5.7
FI (µU/mL): 1.78±0.81 vs. –0.55±0.46
Huyen et al. 
   (2010) [24]
FI, FG, HbA1c, 
HOMA-IR
T0: baseline 
T1: 12 weeks
T0–T1 Changes:
HbA1c (%): 2.0±1.3 vs. 0.2±0.5
FG (mmol/L): –3.0±1.8 vs. –0.6±2.2, P=0.007
FI (pmol/L): –6.0±42.9 vs. –22.5±47.5, P=0.147
HOMA-IR: –2.14±3.05 vs. 1.1±3.27, P=0.023
Hsu et al. 
   (2011) [17]
FI, FG, HOMA-IR, 
HbA1c
T0: baseline 
T1: 16 weeks
T0–T1 Changes:
HbA1c (%): 4.3±9.1 vs. 3.0±9.0, P=0.54
FG (mmol/L): 0.26±1.58 vs. 0.15±1.25, P=0.76
FI (UI/L): 11.0±47.6 vs. –0.4±65.1, P=0.41
HOMA-IR: 11.1± 62.2 vs. 2.4±62.7, P=0.57
Huyen et al. 
   (2013) [25]
FI, FG T0: baseline
T1: 4 weeks
T0–T1 Changes:
FG (mmol/L): –1.9±1.0 vs. –0.2±1.5, P<0.001
FI (pmol/L): –0.23±7.8 vs. –0.3±9.8, P=0.984
Mousavi et al. 
   (2013) [28]
FG T0: baseline 
T1: 8 weeks
FG: T0: 142.0±42.0 vs. 144.3±44.9 ; T1: 143.6±43.9 vs. 142.9±3.2
Lasaite et al. 
   (2014) [26]
HbA1c T0: baseline
T1: 9 months
HbA1c (%): T0: 7.8±1.4 vs. 8.1±2.0; T1: 7.5±1.3 vs. 7.5±1.5
Liu et al. 
   (2014) [19]
FI, FG, HOMA-IR, 
HbA1c
T0: baseline 
T1: 16 weeks
T0–T1 Changes:
FG (mg/dL): 9.0±30.3 vs. –0.6±25.2, P=0.13
HbA1c (%): 0.0±5.5 vs. –0.2±0.6, P=0.24
FI (IU/L): –6.3±10.0 vs. –4.7±13.5, P=0.54
HOMA-IR: –0.20±4.0 vs. 1.3±4.8, P=0.50
Mozaffari-Khosravi 
   et al. (2014) [29]
FG, HOMA-IR T0: baseline
T1: 4 weeks
T0–T1 Changes:
FG (mg/dL): –1.6±26 vs. 1.2±26, P=0.5
HOMA-IR: T0: 1.20 vs. 1.30, P=0.6; T1: 1.60 vs. 1.10, P=0.004
Ryu et al. 
   (2006) [31]
FI, FG, HOMA-IR T0: baseline 
T1: 4weeks
T0- T1 Changes:
FG (mmol/L): 6.7±1.3 vs. 6.9±1.1, P=0.09
FI (µU/mL): 10.29±1.69 vs. 10.40±1.47, P=0.71
HOMA-IR: 2.99±1.71 vs. 3.15±1.51, P=0.45
Values are presented as mean±standard deviation.
FI, fasting insulin; FG, fasting blood glucose; HOMA-IR, homeostatic model assessment for insulin resistance; HbA1c, glycosylated hemoglo-
bin.
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[30], which might be less comparative. One study was exclud-
ed due to the very low report quality [26]. Diet and physical 
activities were controlled in each arm of the six included RCTs. 
These studies were excluded post hoc as we had not anticipated 
this variation prior to extraction. Forest plots depicting the re-
sults of meta-analysis are shown in Fig. 3.
HbA1c
Five studies involving 308 participants provided data for 
HbA1c concentration before and after the intervention (Fig. 
3A) [16,17,19,26,27]. There was no overall difference between 
the treatment and control arms (SMD, –0.32; 95% CI, –0.86 to 
0.23; P=0.25) for all studies. Considerable heterogeneity was 
found in the subgroups of GT/GTE (I²=87%), while the decaf-
feinated GTE group showed consistent results (I²=0%). For 
the subgroup analysis, there was no effect for GT/GTE (SMD, 
–0.50; 95% CI, –1.44 to 0.43; P=0.29) or decaffeinated GTE 
(SMD, –0.04; 95% CI, –0.37 to 0.29; P=0.81) on HbA1c. 
Fasting glucose
Five studies with 326 participants provided information for the 
analysis of fasting glucose at baseline and after the intervention 
(Fig. 3B) [16,17,19,27,28]. No evidence was found that GT/
GTE affects FG levels in comparison to the placebo group 
(SMD, –0.10; 95% CI, –0.50 to 0.30; P=0.61). The heterogene-
ity within the subgroup of GT/GTE was considerable (I²= 
81%); comparatively, the decaffeinated GTE group showed a 
low level of heterogeneity (I²=10%). Findings from subgroup 
analysis showed no effect of the test beverage in both the decaf-
feinated GTE and the GT/GTE groups (SMD, –0.26; 95% CI, 
–0.61 to 0.09; P=0.14) (SMD, 95% CI, 0.02; –0.68 to 0.72; P= 
0.96, respectively).
Fasting insulin
Data from four studies were pooled in to the FI analysis, from 
Table 3. Excluded studies after screening of the full text
Excluded study Reasons for exclusion
MacKenzie et al. (2007) [32] Intervention are combined green tea 
and black tea
Fenercioglu et al. (2010) [33] Intervention are combined green tea 
and pomegranate extract
Stote et al. (2012) [34] Participants are neither T2DM or 
pre-diabetes patients
Vieira Senger et al. (2012) [35] Participants are neither T2DM or 
pre-diabetes patients
Huang et al. (2013) [36] Not RCT
Pham et al. (2014) [37] Participants are neither T2DM or 
pre-diabetes patients
Takahash et al. (2014) [38] No targeted outcomes reported
Keske et al. (2015) [39] Not RCT
Dower et al. (2015) [40] Participants are neither T2DM or 
pre-diabetes patients
Peristiowati et al. (2015) [41] Not RCT
Dostal et al. (2016) [42] Participants are neither T2DM or 
pre-diabetes patients 
Lu et al. (2016) [43] Participants are neither T2DM or 
pre-diabetes patients
T2DM, type 2 diabetes mellitus; RCT, randomized controlled trial.
Fig. 2. Risk of bias summary: review authors’ judgements 
about each risk of bias item for each included study. 
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Fig. 3. Meta-analysis results for each assessed outcome. (A) Comparison between decaffeinated green tea extract and placebo, 
outcome: glycosylated hemoglobin (HbA1c, %). (B) Comparison between decaffeinated green tea extract and green tea extract, 
outcome: fasting glucose. (C) Comparison between decaffeinated green tea extract and green tea extract, outcome: fasting insulin. 
(D) Comparison between decaffeinated green tea extract and green tea extract versus placebo, outcome: homeostatic model as-
sessment for insulin resistance (HOMA-IR). SD, standard deviation; IV, independent variable; CI, confidence interval. 
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which a total of 277 participants were included (Fig. 3C) 
[16,17,19,27]. The overall heterogeneity was substantial 
(I²=63%) among these four studies and considerable for the 
subgroup of GT/GTE (I²=87%). No intervention effect on FI 
was seen overall (SMD, –0.25; 95% CI, –0.64 to 0.15, P=0.23) 
or in subgroup analyses (decaffeinated GTE: SMD, –0.16; 95% 
CI, –0.49 to 0.16; P=0.32) (GT/GTE: SMD, –0.33; 95% CI, 
–1.31 to 0.66; P=0.51).
HOMA-IR
Three studies involving 205 participants were included in the 
HOMA-IR analysis (Fig. 3D); two studies using decaffeinated 
GTE [17,19] and one [16] using GT beverage as the interven-
tion arm. There was no evidence that either intervention was 
effective in improving HOMA-IR (SMD, 0.10; 95% CI, –0.17 
to 0.38; P=0.46). However, due to the insufficient amount of 
studies and the relatively small sample size, this analysis result 
may not be reliable.
DISCUSSION
In total, 11 studies were identified in this systematic review. Of 
these, six studies were included in the meta-analysis. We found 
no evidence of differences between GT/GTE/decaffeinated 
GTE and the placebo for any analyzed outcomes. Within the 
subgroup analyses we found considerable heterogeneity be-
tween studies which may reflect the limited number of studies 
in this field. The general reporting quality of the included stud-
ies was moderate to high. Moreover, eight of the studies in-
cluded in this review were conducted in developing countries, 
where the prevalence rates of T2DM are higher than in devel-
oped nations. Additionally, the types of GT provided in studies 
by [17,19,26,27] were capsules, which may be more convenient 
and acceptable for the T2DM participants than a GT beverage, 
since the drop-out participants cited the unacceptable taste of 
GT as their reason for leaving. However, the cost-effective fac-
tors for using the capsules or the GT bags were not mentioned 
in these studies. It should also be noted that no information for 
this review is available from large-scale programmatic effec-
tiveness trials. Instead, most of the information obtained was 
from small-scale studies using targeted fortification. In addi-
tion, the majority of the studies were carried out in Asian 
countries (n=10), since GT consumption appeared to be more 
acceptable in these countries [21].
This systematic review and meta-analysis comprehensively 
evaluated the effect of GT/GTE on insulin and glycemic pa-
rameters in people with T2DM or pre-diabetes. Studies in-
cluded in this review had been updated from Wang et al. [21], 
in which the findings show no effects of the GT/GTE on 
HbA1c, FG, FI, and HOMA-IR in people at risk of T2DM. 
Compared to the current study, the latest studies included in 
Wang et al. [21] were published in 2011 [15,17]. Moreover, the 
population in Wang et al. [21] included people with T2DM, 
prediabetes, obesity, or metabolic syndrome, where the sub-
group analysis included only four studies of people with 
T2DM or prediabetes patients. Additionally, it might be criti-
cized that the dependent variable in one of the studies in Wang 
et al. [21] did not focus on the T2DM, but on the cardiovascu-
lar disease (CVD). Thus, we updated the literature search up to 
April 2017 to expand the evidence base for individuals with 
T2DM or prediabetes. In this review, six studies on T2DM or 
prediabetes people were pooled into meta-analysis and results 
show consensus evidence with Wang et al. [21]. Although 
these results suggested no effects of GT/GTE in the reduction 
of insulin resistance and the maintenance of glycemic, several 
findings provide evidence for further exploration. For one as-
pect, findings of Nagao et al. [30] in 2009 indicated a reduction 
of HbA1c and fasting glucose levels. For another, in the results 
of a registered trial by Mozaffari-Khosravi et al. [29], GT had 
showed a positive effect on reducing the HOMA-IR level in 
people with T2DM. These two studies were excluded from the 
meta-analysis, since the comparison arm in both studies was 
neither a placebo nor the water, which might be less compara-
tive. However, they provided evidence for the potential effects 
of GT on improving the insulin function. Future studies with 
complete comparisons between GT/GTE and placebo/water 
are required for improving the strength of this evidence. 
In recent years, an increasing amount of research has sug-
gested that GT may favorably modulate insulin sensitivity and 
glucose homeostasis and therefore inhibit the development of 
T2DM [9,44]. A review of experimental studies demonstrate 
that GT plays a role in enhancing insulin sensitivity by improv-
ing the absorption of glucose into skeletal muscle in healthy 
subjects [9]. Evidence from animal studies indicates that the 
GTE could lower blood glucose levels and alleviate insulin re-
sistance in diabetic mice by increasing the expression of glu-
cose transporter IV and improving muscular β-oxidation 
[12,45]. An animal study reported that the increased insulin 
concentrations were found in rats with 23 g GTE feeding per 
day; this study suggested that a higher consumption of GT 
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were beneficial for T2DM prevention [46]. Further, a meta-
analyses included 17 RCTs found that GT/GTE consumptions 
are associated with improved glycemic control and reduced FI 
concentration in healthy subjects as well as in people with obe-
sity, CVD, cancer, and T2DM [20]. Comparatively, different 
findings were found in another meta-analyses, which included 
nine cohort studies to explore the consumption of tea and the 
risk of T2DM [47]. Although results from this meta-analyses 
show no association between the tea consumption and the re-
duced T2DM risk (risk ratio [RR], 0.96; 95% CI, 0.92 to 1.01), 
stratified analyses of this study indicated that >4 cups per day 
tea consumption might related to the prevention of T2DM 
(RR, 0.8; 95% CI, 0.7 to 0.93). Recently, another meta-analysis 
included 10 studies identified that the consumptions of tea 
could alleviate the decrease of fasting blood insulin (1.30 U/L; 
95% CI, 0.36 to 2.24) in T2DM subjects whereas no differences 
found in homeostasis model of insulin resistance 0.38 (95% CI, 
0.18 to 0.95) and fasting blood glucose 0.05 mmol/L (95% CI, 
0.51 to 0.40) [48]. The test tea in both meta-analyses included 
black tea, oolong tea, GT, and a combination of the tea ex-
tracts.
This review has several limitations that should be acknowl-
edged. First, only a small number of studies met the inclusion 
criteria. Second, due to the small number of studies included 
we were unable to repeat our analyses excluding studies of low 
methodological quality, which may have biased our results. 
Moreover, the methodological qualities of some of the includ-
ed studies are relatively low. Finally, the random-effects model 
used in these meta-analyses may achieve better estimates when 
a greater number of studies are included [23]. Thus, since these 
results are inconsistent, further RCTs with larger sample sizes 
and longer duration are needed in the future, in order to have a 
better estimation of the effects of GT/GTE in retarding the de-
velopment of T2DM or its clinical consequences in people 
with T2DM or pre-diabetes. 
As suggested by Bauer et al. [49], the prevention of T2DM is 
a ‘whole-of-life’ task requiring an integrated approach operat-
ing from the origin of the disease. As one of the most popular 
beverages worldwide, tea had been examined in both epidemi-
ological and experimental studies as a possible food supple-
ments for the prevention of T2DM [8,46]. Therefore, any dis-
covery of specific anti-diabetic effects in GT on insulin resis-
tance and glycemic control might ultimately lead to therapeu-
tic modalities that can retard the development of T2DM. 
Based on the present meta-analysis results, in people with 
T2DM, no reductions on the levels of HbA1c, fasting glucose, 
FI, and HOMA-IR were found in GT or GTE treatment 
groups, in comparison with the placebo groups. However, 
findings from the meta-analyses may be limited due to the 
small number of eligible studies. Results may also be affected 
by the limited duration of intervention, varied reporting quali-
ty of the included studies. Therefore, further investigations in 
this field are necessary. Particularly, adequately powered RCTs 
with longer duration of follow-up are needed.
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Appendix 1. Search strategy (MEDLINE)
1. diabetes.af. 
2. diabetes mellitus.af. 
3. type 2 diabetes.af. 
4. T2D.af. 
5. T2DM.af. 
6. "type 2 diabetes mellitus".af. 
7. (insulin adj1 resistance).af. 
8. insulin*.af. 
9. (insulin adj1 sensitivit*).af. 
10. (glucose adj1 control).af.
11. (glycemic adj1 control).af. 
12. (glucose adj1 tolerance).af. 
13. glucose*.af. 
14. glycaemic*.af. 
15. (blood adj1 sugar).af.
16.  1 or 2 or 3 or 4 or 5 or 6 or 7 or 
8 or 9 or 10 or 11 or 12 or 13 or 
14 or 15 
17. (green adj1 tea*).af. 
18. (tea adj1 extract*).af.
19. GT.af. 
20. GTE.af. 
21. EGCG.af. 
22. catechin.af. 
23.  (epigallocatechin adj1 gallate).
af.  
24. epigallocatechin.af. 
25. exp Tea/ 
26.  17 or 18 or 19 or 20 or 21 or 22 
or 23 or 24 or 25 
27.  exp Randomized Controlled 
Trials as Topic/
28. Random Allocation/ 
29. Double-Blind Method/
30. Single-Blind Method/ 
31. Clinical Trial/ 
32. exp Clinical Trials as Topic/
33. clinical trial, phase i.pt.
34. clinical trial, phase ii.pt.
35. clinical trial, phase iii.pt.
36. clinical trial, phase iv.pt.
37. controlled clinical trial.pt.
38.  randomi#ed controlled trial.
pt. 
39. multicenter study.pt.
40. clinical trial.pt. 
41. (clinical adj trial).tw.
42.  ((sing* or doubl* or treb* or 
tripl*) adj (blind* or mask*)).
tw.
43. Placebos/ 
44. placebo*.tw. 
45. exp Placebo Effect/ 
46. random*.tw. 
47. (crossover or cross-over).tw.
48. RCT*.tw. 
49.  ((allocat* or assign*) adj2 ran-
dom*).tw. 
50.  (randomi?ed or randomi? 
ation).tw. 
51. randomly.ab. 
52.  ((administ* or allocat* or as-
sign* or class* or control* or 
determine* or divide* or dis-
tribut* or expose* or fashion* 
or number* or place* or re-
cruit* or substitut* or treat*) 
adj3 random*).tw.
53. drug therapy.fs. 
54. trial.tw. 
55. groups.ab. 
56.  (control* adj3 (trial* or study 
or studies)).tw. 
57.  ((singl* or doubl* or treb* or 
tripl*) adj3 (blind* or mask* or 
dummy*)).tw.
58.  (control* adj3 (trial* or study 
or studies)).tw. 
59.  ((singl* or doubl* or treb* or 
tripl*) adj3 (blind* or mask* or 
dummy*)).mp.
60. Clinical Trial, Phase II/
61. Clinical Trial, Phase III/
62. Clinical Trial, Phase IV/
63.  exp Randomized Controlled 
Trial/
64. exp Pragmatic Clinical Trial/
65.  ((waitlist* or wait* list* or 
treatment as usual or TAU) 
adj3 (control or group)).ab.
66.  27 or 28 or 29 or 30 or 31 or 32 
or 33 or 34 or 35 or 36 or 37 or 
38 or 39 or 40 or 41 or 42 or 43 
or 44 or 45 or 46 or 47 or 48 or 
49 or 50 or 51 or 52 or 53 or 54 
or 55 or 56 or 57 or 58 or 59 or 
60 or 61 or 62 or 63 or 64 or 65
67. 16 and 26 and 66 
68.  (animals not humans).mp. 
[mp=title, abstract, original ti-
tle, name of substance word, 
subject heading word, key-
word heading word, protocol 
supplementary concept word, 
rare disease supplementary 
concept word, unique identifi-
er] 
69. exp Animals, Laboratory/ 
70.  exp Animal Experimentation/ 
71. exp Rats/ 
72. exp Rodentia/ 
73.  (rat* or mouse).mp. or mice.
ti,ab. [mp=title, abstract, orig-
inal title, name of substance 
word, subject heading word, 
keyword heading word, proto-
col supplementary concept 
word, rare disease supplemen-
tary concept word, unique 
identifier] 
74. 68 or 69 or 70 or 71 or 72 or 73
75. 67 not 74
